Bacterial and Fungal Infections
An Introduction to Bacterial and Fungal Infections
The pattern of bacterial infections globally is changing due to global warming, increasing antimicrobial resistance, and population migration. As a result, multidrug-resistant bacteria are increasingly seen in Europe. Immunotherapies, including monoclonal antibodies, checkpoint inhibition, T cell-based immunotherapies and cytokine therapy offer promise as alternative approaches. Fungal infections, particularly invasive infections, are among the most difficult human diseases to manage. Challenges in their treatment include toxicity, interactions, restricted routes of administration, and drug resistance. Therapies in early development include, 2 glucan synthesis inhibitors; fourth-generation azoles; agents with intracellular targets and neurapheresis, a filtration device used as adjunctive therapy for cryptococcosis. Choosing clinical candidates from early studies will be challenging.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Bacterial and Fungal Infections Content
Management of patients with NTM-LD: Improving adherence for optimal outcomes
Watch expert pulmonologists discuss how to optimize the diagnosis and management of patients with NTM-LD
- Appraise strategies to reduce time to diagnosis for patients with NTM-LD
- Utilize guideline recommendations when setting individualized treatment goals for patients with NTM-LD
- Apply strategies to manage adverse events for improved outcomes and adherence in patients with NTM-LD
Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?
touchREVIEWS in Infectious Diseases. 2022;1(1):16–25 DOI: https://doi.org/10.17925/ID.2022.1.1.16
Vaginitis is one of the most common health-related issues that affects women worldwide. It can be caused by bacterial, fungal or protozoal infections. Vulvovaginal candidiasis (VVC) is the second most common cause of vaginitis, accounting for one-third of all cases in women of reproductive age.1 In the USA, VVC results in approximately 1.4 million outpatient visits […]
Kayla Stover Hielscher, IDWeek 2022: Isavuconazole – a good treatment option for Candida species?
Isavuconazole is a once-daily antifungal, used to treat a wide array of fungal infections. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss isavuconazole’s properties and the efficacy and safety compared to other treatment options. The abstract entitled: ‘This Drug for […]
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]
Kayla Stover Hielscher, IDWeek 2022: Linezolid as a treatment option for MRSA bacteraemia
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is one of the more severe forms of MRSA. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss the use of linezolid as a treatment option for MRSA bacteraemia infection. Dr Stover Hielscher discusses drug interactions, […]
Michael Ison: Highlights from IDWeek 2022
In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics. Interviews available in this series: Respiratory syncytial virus (RSV) – Health burden […]
Martin Hoenigl, IDWeek 2022: Candidemia prognosis and unmet needs in its treatment
Candidemia is the one of the most common form of invasive candidiasis, and in some countries the most common causes of bloodstream infections in hospitalized patients. In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss the prognosis of candidemia, the unmet needs in its treatment, and […]
Martin Hoenigl, IDWeek 2022: Guideline adherence predicts outcomes of candidemia in Europe
In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss ECMM Candida III Multinational European study, which collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe, to assess how adherence to guideline recommendations correlate with outcomes. The abstract entitled: ‘Guideline Adherence […]
The patient pathway to diagnosis for non-cystic fibrosis bronchiectasis
MDT specialists and a patient with non-cystic fibrosis (non-CF) bronchiectasis discuss the pathophysiology, comorbidities and the pathway to diagnosis
- Describe the pathophysiology and comorbidities of non-CF bronchiectasis
- Appraise the clinical presentations of non-CF bronchiectasis
- Analyse the methodologies to diagnose non-CF bronchiectasis
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!